Raising Early Stage Investments

Raising Early Stage Investments was a panel topic at the Medtech Showcase in January.

Among the points that caught my ear:

• Joseph Gulfo: When you raise public money, ask (1) What is the maximum percent of a company the investor can own and (2) What is the investor’s minimum bite size? These help you determine if you’ll get their money.

• Justin Klein, NEA: Raise an amount of capital that funds a substantial risk reduction in your company, that sets up the next phase in the company’s development for existing investors, new investors, and your management team.

• Lara Abbaschian, Lightstone Ventures: For every thousand introductions, we will take 300 meetings. From those, we will do diligence on maybe 75 and maybe 4 deals. She invests 10-15MM in an average deal size over the course of an investment; it depends who we are syndicating with, how many additional rounds we think will be necessary.

• Derrick Li, TPP Healthcare: China throws a wrench into how traditional venture capitalists make valuations because the typical Chinese company wants to find a hot commodity and make a ridiculous valuation. But the traditional US venture capitalist brings a lot of non-quantitative assets to the table.

• Gulfo: Having strategic partners and having a concept within the investor’s specialty will help your case.

• Abbaschian: A small market with a straightforward trial to run de-risks your investment, making a smaller market more appealing. When you’re talking about a big market like Type II diabetes, you increase the investor’s risk.

• Klein: It’s harder to predict when an investment will mature versus the price for which it will mature. The best outcomes come when you’re not trying to sell a company to achieve some number but when you can generate competitive interest from multiple potential buyers. An average investment from us is $30MM and our goal is a $100MM gain, a 4x multiple. Anything less than 3x is not going to fly and our bandwidth is an issue when you consider overseeing the company.

• Abbaschian: We might talk to a company for a year before investing. You don’t just want someone to write a check, you want good partners, those who will add value beyond the check.

• Klein: When talking Friends and Family (non-institutional money), do it in the form of a convertible note that gives an appropriate discount to convert into a price per share at your next equity financing and this will avoid a down round.

Klein expects we’ll see regulatory loosening and up to 10 IPOs this year, each doing at least $25MM in revenue.

If you found this post useful, your peers will thank you for sharing it!

Speak Your Mind


This site uses Akismet to reduce spam. Learn how your comment data is processed.